Open Access

Identification of an eight-lncRNA prognostic model for breast cancer using WGCNA network analysis and a Cox‑proportional hazards model based on L1-penalized estimation

  • Authors:
    • Zhenbin Liu
    • Menghu Li
    • Qi Hua
    • Yanfang Li
    • Gang Wang
  • View Affiliations

  • Published online on: August 6, 2019     https://doi.org/10.3892/ijmm.2019.4303
  • Pages: 1333-1343
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

An ever‑increasing number of long noncoding (lnc)RNAs has been identified in breast cancer. The present study aimed to establish an lncRNA signature for predicting survival in breast cancer. RNA expression profiling was performed using microarray gene expression data from the National Center for Biotechnology Information Gene Expression Omnibus, followed by the identification of breast cancer‑related preserved modules using weighted gene co‑expression network (WGCNA) network analysis. From the lncRNAs identified in these preserved modules, prognostic lncRNAs were selected using univariate Cox regression analysis in combination with the L1‑penalized (LASSO) Cox‑proportional Hazards (Cox‑PH) model. A risk score based on these prognostic lncRNAs was calculated and used for risk stratification. Differentially expressed RNAs (DERs) in breast cancer were identified using MetaDE. Gene Set Enrichment Analysis pathway enrichment analysis was conducted for these prognostic lncRNAs and the DERs related to the lncRNAs in the preserved modules. A total of five preserved modules comprising 73 lncRNAs were mined. An eight‑lncRNA signature (IGHA1, IGHGP, IGKV2‑28, IGLL3P, IGLV3‑10, AZGP1P1, LINC00472 and SLC16A6P1) was identified using the LASSO Cox‑PH model. Risk score based on these eight lncRNAs could classify breast cancer patients into two groups with significantly different survival times. The eight‑lncRNA signature was validated using three independent cohorts. These prognostic lncRNAs were significantly associated with the cell adhesion molecules pathway, JAK‑signal transducer and activator of transcription 5A pathway, and erbb pathway and are potentially involved in regulating angiotensin II receptor type 1, neuropeptide Y receptor Y1, KISS1 receptor, and C‑C motif chemokine ligand 5. The developed eight‑lncRNA signature may have clinical implications for predicting prognosis in breast cancer. Overall, this study provided possible molecular targets for the development of novel therapies against breast cancer.

References

1 

McGuire A, Brown JA, Malone C, Mclaughlin R and Kerin MJ: Effects of age on the detection and management of breast cancer. Cancers. 7:908–929. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Radice D and Redaelli A: Breast cancer management: Quality-of-life and cost considerations. Pharmacoeconomics. 21:383–396. 2003. View Article : Google Scholar : PubMed/NCBI

3 

Jiralerspong S and Goodwin PJ: Obesity and breast cancer prognosis: Evidence, challenges, and opportunities. J Clin Oncol. 34:4203–4216. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Kitagawa M, Kitagawa K, Kotake Y, Niida H and Ohhata T: Cell cycle regulation by long non-coding RNAs. Cell Mol Life Sci. 70:4785–4794. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Liz J and Esteller M: lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 1859:169–176. 2016. View Article : Google Scholar

6 

Hayes EL and Lewis-Wambi JS: Mechanisms of endocrine resistance in breast cancer: An overview of the proposed roles of noncoding RNA. Breast Cancer Res. 17:402015. View Article : Google Scholar : PubMed/NCBI

7 

Godinho MF, Sieuwerts AM, Look MP, Meijer D, Foekens JA, Dorssers LC and van Agthoven T: Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer. 103:1284–1291. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Sørensen KP, Thomassen M, Tan Q, Bak M, Cold S, Burton M, Larsen MJ and Kruse TA: Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Breast Cancer Res Treat. 142:529–536. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC and Yu J: LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 35:2746–2755. 2016. View Article : Google Scholar :

10 

Li Z, Hou P, Fan D, Dong M, Ma M, Li H, Yao R, Li Y, Wang G and Geng P: The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ. 24:59–71. 2017. View Article : Google Scholar :

11 

Tracy KM, Tye CE, Page NA, Fritz AJ, Stein JL, Lian JB and Stein GS: Selective expression of long non-coding RNAs in a breast cancer cell progression model. J Cell Physiol. 233:1291–1299. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Meng J, Li P, Zhang Q, Yang Z and Fu S: A four-long non-coding RNA signature in predicting breast cancer survival. J Exp Clin Cancer Res. 33:842014. View Article : Google Scholar : PubMed/NCBI

13 

Sun M, Wu D, Zhou K, Li H, Gong X, Wei Q, Du M, Lei P, Zha J and Zhu H: An eight-lncRNA signature predicts survival of breast cancer patients: A comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network. Breast Cancer Res Treat. 175:59–75. 2019. View Article : Google Scholar : PubMed/NCBI

14 

Maubant S, Tesson B, Maire V, Ye M, Rigaill G, Gentien D, Cruzalegui F, Tucker GC, Roman-Roman S and Dubois T: Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. PLoS One. 10:e01223332015. View Article : Google Scholar : PubMed/NCBI

15 

Colak D, Nofal A, Albakheet A, Nirmal M, Jeprel H, Eldali A, Al-Tweigeri T, Tulbah A, Ajarim D, Malik OA, et al: Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One. 8:e632042013. View Article : Google Scholar : PubMed/NCBI

16 

Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, et al: Correlating transcriptional networks to breast cancer survival: A large-scale coexpression analysis. Carcinogenesis. 34:2300–2308. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Carvalho B: An Introduction to the Oligo Package. 2009.

18 

Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI

19 

O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, Rajput B, Robbertse B, Smith-White B, Ako-Adjei D, et al: Reference sequence (RefSeq) database at NCBI: Current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 44:D733–D745. 2016. View Article : Google Scholar :

20 

Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al: Clustal W and clustal X version 2.0. Bioinformatics. 23:2947–2948. 2007. View Article : Google Scholar : PubMed/NCBI

21 

Lou Y, Tian GY, Song Y, Liu YL, Chen YD, Shi JP and Yang J: Characterization of transcriptional modules related to fibrosing-NAFLD progression. Sci Rep. 7:47482017. View Article : Google Scholar : PubMed/NCBI

22 

Perumal D, Leshchenko VV, Kuo PY, Jiang Z, Readhead B, Eden C, Athaluri Divakar SK, Zhang W, Cho HJ, Chari A, et al: Weighted gene co-expression network analysis (WGCNA) identifies highly proliferative myeloma subgroup responsive to CDK4/ARK5 inhibition. Blood. 124:34452014.

23 

Horvath S and Langfelder P: Tutorials for the WGCNA package for R: WGCNA Background and glossary. 2011.

24 

Tibshirani R: The lasso method for variable selection in the Cox model. Stat Med. 16:385–395. 1997. View Article : Google Scholar : PubMed/NCBI

25 

Huang S, Yee C, Ching T, Yu H and Garmire LX: A novel model to combine clinical and pathway-based transcriptomic information for the prognosis prediction of breast cancer. PLoS Comput Biol. 10:e10038512014. View Article : Google Scholar : PubMed/NCBI

26 

Chong QI, Hong L, Cheng Z and Yin Q: Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysis. Oncol Lett. 11:568–574. 2016. View Article : Google Scholar

27 

Walker MG and Shi J: Gene set enrichment analysis (GSEA) for interpreting gene expression profiles. Current Bioinformatics. 2:133–137. 2007. View Article : Google Scholar

28 

Evans JR, Feng FY and Chinnaiyan AM: The bright side of dark matter: lncRNAs in cancer. J Clin Invest. 126:27752016. View Article : Google Scholar : PubMed/NCBI

29 

Shen Y, Katsaros D, Loo LW, Hernandez BY, Chong C, Canuto EM, Biglia N, Lu L, Risch H, Chu WM and Yu H: Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer. Oncotarget. 6:8579–8592. 2015.PubMed/NCBI

30 

Shen Y, Wang Z, Loo LW, Ni Y, Jia W, Fei P, Risch HA, Katsaros D and Yu H: LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer. Breast Cancer Res Treat. 154:473–482. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Lu P, Yang X, Yang Y, Wang F, Li L and Gu Y: Linc00472 suppresses breast cancer progression and enhances doxorubicin sensitivity through regulation of miR-141 and programmed cell death 4. Rsc Advances. 8:8455–8468. 2018. View Article : Google Scholar

32 

Mcsherry EA, Brennan K, Hudson L, Hill AD and Hopkins AM: Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of rap1 GTPase. Breast Cancer Res. 13:R312011. View Article : Google Scholar : PubMed/NCBI

33 

Li DM and Feng YM: Signaling mechanism of cell adhesion molecules in breast cancer metastasis: Potential therapeutic targets. Breast Cancer Res Treat. 128:7–21. 2011. View Article : Google Scholar : PubMed/NCBI

34 

Christy J and Priyadharshini L: Differential expression analysis of JAK/STAT pathway related genes in breast cancer. Meta Gene. 16:2018. View Article : Google Scholar

35 

Hosford SR and Miller TW: Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmacogenomics Pers Med. 6:203–215. 2014.

36 

Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L and Bloom KJ: The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist. 8:307–325. 2003. View Article : Google Scholar : PubMed/NCBI

37 

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI

38 

Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, et al: HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol. 9:586–600. 2015. View Article : Google Scholar

39 

De Cola A, Volpe S, Budani MC, Ferracin M, Lattanzio R, Turdo A, D'Agostino D, Capone E, Stassi G, Todaro M, et al: MiR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death Dis. 6:e18232015. View Article : Google Scholar : PubMed/NCBI

40 

Oh E, Kim JY, Cho Y, An H, Lee N, Jo H, Ban C and Seo JH: Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis. Biochim Biophys Acta. 1863:1071–1081. 2016. View Article : Google Scholar : PubMed/NCBI

41 

Liu L, Xu Q, Cheng L, Ma C, Xiao L, Xu D, Gao Y, Wang J and Song H: NPY1R is a novel peripheral blood marker predictive of metastasis and prognosis in breast cancer patients. Oncol Lett. 9:891–896. 2015. View Article : Google Scholar : PubMed/NCBI

42 

Goertzen CG, Dragan M, Turley E, Babwah AV and Bhattacharya M: KISS1R signaling promotes invadopodia formation in human breast cancer cell via β-arrestin2/ERK. Cell Signal. 28:165–176. 2016. View Article : Google Scholar : PubMed/NCBI

43 

Gao D, Rahbar R and Fish EN: CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells. Open Biol. 6:1601222016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 44 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, Z., Li, M., Hua, Q., Li, Y., & Wang, G. (2019). Identification of an eight-lncRNA prognostic model for breast cancer using WGCNA network analysis and a Cox‑proportional hazards model based on L1-penalized estimation. International Journal of Molecular Medicine, 44, 1333-1343. https://doi.org/10.3892/ijmm.2019.4303
MLA
Liu, Z., Li, M., Hua, Q., Li, Y., Wang, G."Identification of an eight-lncRNA prognostic model for breast cancer using WGCNA network analysis and a Cox‑proportional hazards model based on L1-penalized estimation". International Journal of Molecular Medicine 44.4 (2019): 1333-1343.
Chicago
Liu, Z., Li, M., Hua, Q., Li, Y., Wang, G."Identification of an eight-lncRNA prognostic model for breast cancer using WGCNA network analysis and a Cox‑proportional hazards model based on L1-penalized estimation". International Journal of Molecular Medicine 44, no. 4 (2019): 1333-1343. https://doi.org/10.3892/ijmm.2019.4303